News Headlines

  1. WIRB-Copernicus Group Partners With Veeva Systems Inc.
    11/17/2017

    WIRB-Copernicus Group (WCG), the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, recently announced that it is partnering with Veeva Systems Inc. to improve the speed and accuracy of institutional review board (IRB) document transfer.

  2. Enrolment Of First Cohort Completed With Eighth Participant Dosed In Cynata’s World First Clinical Trial
    11/16/2017

    Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to provide an update on the progress of the clinical trial of its lead Cymerus™ mesenchymal stem cell (MSC) product CYP-001.

  3. CRF Health’s TrialMax Touch® Selected By Leading Specialty Pharmaceutical Company For Pediatric Rare Disease Phase II Study
    11/14/2017

    CRF Health, the leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, has been selected by a leading specialty pharmaceutical company for its latest pediatric rare disease Phase II study.

  4. Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program In Patients With Rare Hyperlipidemias
    11/14/2017

    Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the initiation of an exploratory Phase 2 program of AKCEA-ANGPTL3-LRx in patients with rare hyperlipidemias.

  5. CEL-SCI Announces Update On Arbitration Against Former Clinical Research Organization
    11/13/2017

    CEL-SCI Corporation announced recently an update on its arbitration with its former clinical research organization (CRO). The last witness in the arbitration hearing testified on Wednesday, November 8, 2017, and no further witnesses or testimony are expected.

  6. International Stem Cell Corporation Announces Positive Interim Clinical Results For Parkinson's Disease Clinical Trial
    11/13/2017

    International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the positive six months interim results of the first cohort of Parkinson’s disease (PD) patients receiving 30 million ISC-hpNSC cells in the ongoing clinical study.

  7. Comprehend Systems Appoints New CEO In Response To Surging Demand For Clinical Intelligence Solutions
    11/13/2017

    Comprehend Systems, Inc., the leader in Clinical Intelligence solutions, has named Terry Cunningham CEO. Cunningham will focus on scaling Comprehend in response to explosive customer demand for solutions that reduce time and risk in clinical trials.

  8. Abeona Enrolls First Subject In Spain In Ongoing Phase 1/2 Clinical Trial In MPS IIIA
    11/10/2017

    Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare diseases, announced today that the first patient was enrolled in the Company’s ABO-102 Phase 1/2 clinical trial at the Hospital Clinico Universitario of Santiago de Compostela, Spain.

  9. Elligo Health Research And PatientLink Partnership Brings New Opportunities For Physicians And Their Patients
    11/9/2017

    Elligo Health Research, a leading clinical research infrastructure provider that brings together sponsors, physicians, patients and CROs to improve clinical trial access and efficiency, is now connecting physicians and patients to treatment options through a new partnership with PatientLink Enterprises, an innovative medical patient data collection and enrollment software development company.

  10. RedHill Biopharma Announces Last Patient Enrolled In The Phase III Study With RHB-104 For Crohn’s Disease
    11/9/2017

    RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the last patient has been enrolled in the Phase III study with RHB-104 for Crohn’s disease (MAP US study).